Valuation: Tengion, Inc.

Market Cap 110K 96.23K 88.7K 83.04K 156K 10.35M 159K 1.07M 413K 5.12M 412K 403K 17.74M P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 5.55M 4.87M 4.49M 4.2M 7.88M 524M 8.04M 53.93M 20.87M 259M 20.85M 20.39M 898M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
+3.15%+7.08%-33.84%-38.11% 567M
+11.25%+6.71%+191.99% - 411M
+0.60%+1.83%+62.93%+114.10% 130M
-3.73%-11.21%-39.96%+2.20% 121M
Average +2.82%+0.58%+45.28%+26.07% 307.31M
Weighted average by Cap. +4.91%+4.25%+51.29%-7.97%

Financials

2012 2013
Net sales - -
Net income -16.93M -14.84M -13.68M -12.81M -24.02M -1.6B -24.52M -164M -63.63M -789M -63.57M -62.18M -2.74B -18.93M -16.6M -15.3M -14.32M -26.85M -1.79B -27.41M -184M -71.14M -882M -71.07M -69.52M -3.06B
Net Debt 3.73M 3.27M 3.02M 2.82M 5.3M 352M 5.41M 36.26M 14.03M 174M 14.02M 13.71M 603M 5.44M 4.77M 4.4M 4.12M 7.72M 513M 7.88M 52.86M 20.46M 254M 20.43M 19.99M 880M
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-